Eastern Equine Encephalitis - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Eastern Equine Encephalitis - Pipeline Review, H2 2015’, provides an overview of the Eastern Equine Encephalitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Eastern Equine Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eastern Equine Encephalitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Eastern Equine Encephalitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Eastern Equine Encephalitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Eastern Equine Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Eastern Equine Encephalitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Eastern Equine Encephalitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Eastern Equine Encephalitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Eastern Equine Encephalitis Overview 6
Therapeutics Development 7
Pipeline Products for Eastern Equine Encephalitis - Overview 7
Pipeline Products for Eastern Equine Encephalitis - Comparative Analysis 8
Eastern Equine Encephalitis - Therapeutics under Development by Companies 9
Eastern Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes 10
Eastern Equine Encephalitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Eastern Equine Encephalitis - Products under Development by Companies 13
Eastern Equine Encephalitis - Products under Investigation by Universities/Institutes 14
Eastern Equine Encephalitis - Companies Involved in Therapeutics Development 15
AlphaVax, Inc. 15
AltraVax Inc. 16
EpiVax, Inc. 17
Profectus BioSciences, Inc. 18
Eastern Equine Encephalitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 24
equine encephalitis vaccine - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
equine encephalitis vaccine - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
equine encephalitis vaccine - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
equine encephalitis vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
TSI-GSD-104 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Eastern Equine Encephalitis - Dormant Projects 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 30
Disclaimer 31
List Of Tables
Number of Products under Development for Eastern Equine Encephalitis, H2 2015 7
Number of Products under Development for Eastern Equine Encephalitis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Eastern Equine Encephalitis - Pipeline by AlphaVax, Inc., H2 2015 15
Eastern Equine Encephalitis - Pipeline by AltraVax Inc., H2 2015 16
Eastern Equine Encephalitis - Pipeline by EpiVax, Inc., H2 2015 17
Eastern Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 20
Number of Products by Stage and Route of Administration, H2 2015 21
Number of Products by Stage and Molecule Type, H2 2015 23
Eastern Equine Encephalitis - Dormant Projects, H2 2015 29
List Of Figures
Number of Products under Development for Eastern Equine Encephalitis, H2 2015 7
Number of Products under Development for Eastern Equine Encephalitis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Top 10 Molecule Types, H2 2015 22
Number of Products by Stage and Top 10 Molecule Types, H2 2015 22
